Form 4: MapLight Therapeutics Executive Sells Shares for Taxes

Jonathan Gillis, CAAO and PAO of MapLight Therapeutics, sold 3,590 shares to cover statutory tax withholding obligations.

Summary

• Jonathan Gillis, Chief Accounting Officer and Principal Accounting Officer, sold 3,590 shares of Voting Common Stock on April 15, 2026.
• The shares were sold at a weighted average price of $26.61 per share.
• The transaction was executed to satisfy statutory tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, the reporting person retains beneficial ownership of 251,054 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share sale is purely administrative and related to tax obligations rather than a change in management sentiment.

Positives

• The sale was non-discretionary, specifically conducted to satisfy tax obligations associated with equity vesting.

Negatives

• Reduction in direct equity holdings by a key accounting officer.

Risks

• None identified; this is a routine regulatory filing regarding tax-related share disposition.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a standard administrative disclosure common in the biotechnology sector, where executive compensation packages heavily utilize restricted stock units, necessitating periodic 'sell-to-cover' transactions for tax compliance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive equity management.
• The use of 'sell-to-cover' for tax obligations is a routine practice among publicly traded biotech firms such as Amgen or Biogen.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was for tax compliance purposes.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, SEC Filing, Equity Vesting, Tax Withholding